Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials
- 1 December 2003
- journal article
- review article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 18 (12) , 1206-1210
- https://doi.org/10.1007/s00467-003-1290-2
Abstract
Calcimimetic agents are small organic molecules that act as allosteric activators of the calcium sensing receptor (CaSR). In parathyroid cells, they lower the threshold for receptor activation by extracellular calcium ions and diminish parathyroid hormone (PTH) secretion. Calcimimetic compounds thus represent a novel way of controlling excess PTH secretion in clinical disorders such as secondary hyperparathyroidism (SHPT) due to chronic renal failure. Clinical trials have documented that the calcimimetic agent cinacalcet hydrochloride effectively lowers plasma PTH levels without increasing serum calcium or phosphorus concentrations in adult hemodialysis patients with SHPT. Serum phosphorus levels and values for the calcium-phosphorus ion product in serum often decline as plasma PTH levels fall during treatment. Experimental evidence suggests that calcimimetic agents may also impede the development of parathyroid gland hyperplasia, an integral component of SHPT due to chronic renal failure. Calcimimetic agents have considerable potential, therefore, as part of new therapeutic strategies for SHPT.Keywords
This publication has 25 references indexed in Scilit:
- The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidismKidney International, 2003
- The Calcimimetic Agent AMG 073 Lowers Plasma Parathyroid Hormone Levels in Hemodialysis Patients with Secondary HyperparathyroidismJournal of the American Society of Nephrology, 2002
- Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal DiseaseHypertension, 2001
- Recent developments in the management of secondary hyperparathyroidismKidney International, 2001
- Expression of extracellular calcium-sensing receptor in human osteoblastic MG-63 cell line.American Journal of Physiology-Cell Physiology, 2001
- Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidismKidney International, 2000
- The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.Journal of Clinical Investigation, 1997
- Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat.Journal of Clinical Investigation, 1986
- Direct ComparisonIn VivoandIn Vitroof Suppressibility of Parathyroid Function by Calcium in Primary Hyperparathyroidism*Journal of Clinical Endocrinology & Metabolism, 1979
- Increased Growth after Long-Term Oral 1α,25-Vitamin D3in Childhood Renal OsteodystrophyNew England Journal of Medicine, 1978